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We hypothesised that individuals with immunological sensitisation to Mycobacterium tuberculosis 24 
(Mtb), conventionally regarded as evidence of latent tuberculosis infection (LTBI), would 25 
demonstrate binary responses to preventive therapy (PT), reflecting the differential 26 
immunological consequences of the sterilisation of viable infection in those with active Mtb 27 
infection versus no Mtb killing in those who did not harbour viable bacilli. 28 
 29 
We investigated longitudinal whole blood transcriptional profile responses to PT of Interferon 30 
gamma release assay (IGRA)-positive tuberculosis contacts and IGRA-negative, tuberculosis-31 
unexposed controls. Longitudinal unsupervised clustering analysis with a subset of 474 most 32 
variable genes in antigen-stimulated blood separated the IGRA-positive participants into two 33 
distinct subgroups, one of which clustered with the IGRA-negative controls. 117 probes were 34 
differentially expressed over time between the two cluster groups, many of them associated with 35 
immunological pathways important in mycobacterial control.  36 
 37 
We contend that the differential host RNA response reflects lack of Mtb viability in the group that 38 
clustered with the IGRA-negative unexposed controls, and Mtb viability in the group (1/3 of IGRA-39 
positives) that clustered away.  40 
 41 
Gene expression patterns in the blood of IGRA-positive individuals emerging during the course of 42 
PT, which reflect Mtb viability, could have major implications in the identification of risk of 43 
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1 INTRODUCTION 50 
 51 
The term latent tuberculosis infection (LTBI) is loaded with the inference that viable 52 
Mycobacterium tuberculosis (Mtb) organisms are present in the affected individual which, under 53 
the right circumstances, have the capacity to cause reactivation and TB disease. Tests of 54 
immunological reactivity, whether delayed type hypersensitivity reactions measured in the 55 
tuberculin skin test (TST) or T lymphocyte stimulation though antigen recognition in the interferon 56 
gamma release assays (IGRAs) are widely referred to as tests for LTBI [1].  57 
 58 
However, neither approach demonstrates presence of viable Mtb bacilli and there is no 59 
histopathological hallmark of LTBI. The lifetime risk of reactivation disease from an Mtb infection 60 
acquired remotely in time is around 10% [2]. In the interval between acquisition of infection and 61 
development of disease, Mtb maintains viability and is assumed to be slowly replicating, either 62 
under close immunological control or in a relatively immunologically privileged location. Thus, LTBI 63 
induces immunological sensitisation as reflected in the TST and IGRA, tests that demonstrate 64 
immunological memory for prior exposure to mycobacterial antigens. 65 
 66 
Nevertheless, 90% of individuals demonstrating immunological recognition of Mtb antigens by 67 
positive IGRA or TST never develop active TB disease. Taking the inherent assumption that TST and 68 
IGRA are indicators of LTBI to its logical conclusion, the 90% who escape development of TB do so 69 
because the immune control-pathogen balance remains in favour of the human host. An 70 
alternative explanation might be that a large proportion of those with positive TST and IGRA 71 
testing do not harbour viable organisms and are thus incapable of progressing to reactivation TB. 72 
 73 
Preventive therapy (PT), in which a limited course of anti-TB antibiotics is used to sterilise 74 
presumed viable infection in individuals with positive TST and/or IGRA tests, has been shown to be 75 
highly effective in reducing the risk of future TB disease [3]. 76 
 77 
We hypothesised that differentiation of LTBI with viable bacilli from immunological sensitisation 78 
without viable infection could be achieved by investigating the whole blood transcriptomic 79 
response to effective PT. We hypothesised that mycobacterial killing from effective LTBI PT would 80 









whom there were no Mtb to be killed, whether these were IGRA/TST positive or healthy IGRA/TST 82 
negative controls with no known prior TB exposure.  83 
 84 
2 MATERIALS AND METHODS 85 
 86 
2.1 Ethics statement 87 
The study procedures and protocol were approved by City & East NHS Research Ethics Committee, 88 
London (reference 16/LO/1206) and the London School of Hygiene and Tropical Medicine 89 
Research Ethics Committee (reference 11603). Written informed consent was given by all 90 
participants before inclusion in the study.   91 
 92 
2.2 Participants 93 
Study participants were recruited from National Health Service (NHS) tuberculosis (TB) outpatient 94 
clinics in London (Whittington Health NHS Trust, Royal Free London NHS Foundation Trust, Barts 95 
Health NHS Trust, Homerton University Hospital NHS Foundation Trust). Healthy controls were 96 
recruited from the London School of Hygiene and Tropical Medicine. 97 
 98 
Participants were recruited who were aged 18 years and above, had positive Interferon Gamma 99 
Release Assay (IGRA) (performed by the local hospital laboratories, using the QuantiFERON-TB 100 
Gold In-tube assay [Qiagen, Manchester, UK]), with known exposure to an index person with 101 
isoniazid- and rifampicin- susceptible pulmonary TB (contact history unconfirmed for three 102 
individuals) and who planned to initiate a 12-week course of combined rifampicin/ isoniazid (RH) 103 
as preventive therapy (once daily rifampicin 600 mg/ isoniazid 300 mg as Rifinah) plus once daily 104 
pyridoxine 10 mg.  Adult volunteers aged 18 years and above were recruited as healthy control 105 
participants. 106 
 107 
Once consented, demographic information, TB exposure history, and medical history were 108 
recorded on a data capture sheet and testing for human immunodeficiency virus (HIV) was 109 
performed. Healthy volunteers additionally underwent IGRA testing (performed using the 110 
QuantiFERON-TB Gold In-tube assay according to the manufacturer’s recommendations) and were 111 
excluded if they were found to be IGRA+. Individuals were excluded if they had a prior history of 112 
TB infection, of having taken anti-TB treatment or exposure to drug-resistant TB. Participants who 113 










including HIV and those who had taken immunosuppressant medication in the preceding six 115 
months were also excluded. Healthy control participants reporting prior exposure to TB were also 116 
excluded. 117 
 118 
Healthy controls were given a two-week course of RH (once daily rifampicin 600 mg/ isoniazid 300 119 
mg as Rifinah) plus once daily pyridoxine 10 mg.  120 
 121 
Blood samples were collected from all participants at baseline (V1) and 2 weeks after initiating RH 122 
(V2), with an additional sample point in IGRA+ participants within 6 weeks of completion of the 123 
12-week course of treatment (V3). At all sampling timepoints, all participants were asked about 124 
their adherence to treatment, and whole blood was collected in a PAXgene blood RNA tube 125 
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) for RNA expression analysis and a lithium 126 
heparin tube (Becton Dickinson, Berkshire, UK) for subsequent stimulation assays. The PAXgene 127 
tubes were frozen within 4 hours of collection. 128 
 129 
2.3 Stimulation of whole blood 130 
Stimulation was performed using QuantiFERON-TB Gold Plus In-tube Assay (QFT-TB Plus) (Qiagen). 131 
Within four hours of collection, 1 ml of blood was transferred from the lithium heparin tube to 132 
each of the four QFT-TB Plus tubes: TB1 antigen, TB2 antigen (both containing peptides from 133 
ESAT-6 and CFP-10 antigens), mitogen positive control and (unstimulated) negative control. The 134 
tubes were gently shaken to dissolve the lyophilized peptides in the blood. The QFT-TB Plus tubes 135 
were immediately incubated upright at 37
o
C for 22 -24 hours. After incubation, the blood was 136 
transferred into a 1.5 ml microcentrifuge tube and centrifuged for 15 minutes at 3000 RCF(g). 137 
Supernatants were removed and the remaining cell pellet (500 µl) was transferred into a 15 ml 138 
tube containing 2.5 ml RNAprotect® Cell Reagent (Qiagen). The cells were resuspended by 139 
vortexing, and incubated for 2 hours for complete cell lysis before freezing at -80°C.  140 
 141 
2.4 Peripheral blood RNA expression by microarray 142 
Total RNA was extracted from the PAXgene tubes using the PAXgene Blood miRNA Kit (Qiagen), 143 
and from the QFT-TB Plus stimulated samples, which had been lysed in RNAprotect, using the 144 
RNEasy mini kit (Qiagen), according to the manufacturer’s instructions, incorporating on-column 145 










quantified by Nanodrop and the quality was assessed using an Agilent Bioanalyzer (Agilent, 147 
Cheshire, UK. The two-color low input Quick Amp Labelling kit (Agilent) was used to Cy3- or Cy5-148 
fluorescently label cRNA samples, which were then hybridized to SurePrint G3 Human Gene 149 
Expression 60K GeneChip microarrays (Agilent) according to the manufacturer’s instructions. 150 
Hybridization intensity was quantified via a SureScan Microarray Scanner (Agilent).  Microarray 151 
data are deposited at Gene Expression Omnibus, Series GSE153342. 152 
     153 
Individual channel intensities from the GeneChip data were extracted independently and analysed 154 
as separate observations [4]. 155 
 156 
2.5 Statistical analyses 157 
Clinical data were analysed using ‘R’ Language and Environment for Statistical Computing 3.5.2. 158 
Fishers, Chi-squared and Kruskall Wallis tests of significance were used for categorical data. Mann-159 
Whitney U tests of significance were used for continuous data. 160 
 161 
Expression data were analysed using ‘R’ Language and Environment for Statistical Computing 162 
3.5.2. Pre-processing, log-2 transformation and normalisation were performed using the Agilp 163 
package [5].  Microarrays were run using two batches of microarray slides and Principal 164 
Component Analysis identified an associated batch effect. Batch correction was performed using 165 
the COmBat function in the Surrogate Variable Analysis (sva) package in R [6, 7]. To minimise the 166 
potential influence of batch correction on subsequent clustering analyses, no reference batch was 167 
used and independent COmBat-corrections were performed for each dataset of interest 168 
(individual PAXgene, TB1 and TB2 tube datasets and a combined TB1/ TB2/ negative tube dataset). 169 
Post-Combat correction PCA plots were undertaken to confirm the removal of the batch effect and 170 
identify outliers.  171 
 172 
Differential gene expression analysis was performed using the limma package in R [8] which uses 173 
linear models. Where paired samples were available and analysis was relevant, paired t-tests were 174 
performed, with this being stated in the results. Adjustment for false discovery rate was 175 
performed using Benjamini-Hochberg (BH) correction with a significance level of adjusted p-value 176 











Prior to longitudinal analyses, the gene expression set was filtered to remove noise. Lowly 179 
expressed transcripts for which expression values did not exceed a value of 6 for any of the 180 
samples, were removed. Transcripts with extreme outlying values were removed, which were 181 
defined as values < (Quartile1 – [3* Inter-Quartile Range]) or > (Quartile3 + [3 * Inter-Quartile 182 
Range]). Transcripts with the greatest temporal and interpersonal variability were then selected 183 
based on their variance, with those transcripts with variance >0.1 taken forwards to the 184 
longitudinal analysis. X-chromosome transcripts which were significantly differentially expressed 185 
with gender at V1, V2 and/ or V3 were identified using linear models in limma (BH corrected p 186 
value < 0.05) and were excluded, as were Y-chromosome transcripts.  187 
 188 
Unsupervised longitudinal clustering analyses were performed using the BClustLong package in ‘R’  189 
[9], which uses a Dirichlet process mixture model for clustering longitudinal gene expression data.  190 
A linear mixed-effects framework is used to model the trajectory of genes over time and it bases 191 
clustering on the regression coefficients obtained from all genes. 500 iterations were run (thinning 192 
by 2, so 1000 iterations in total).  193 
 194 
Longitudinal differential gene expression analyses were performed using the MaSigPro package in 195 
R [10]. MaSigPro follows a two-step regression strategy to find genes with significant temporal 196 
expression changes and significant differences between groups. Coefficients obtained in the 197 
second regression model are then used to cluster together significant genes with similar 198 
expression patterns. Adjustment for false discovery rate was performed using BH correction with a 199 
significance level of adjusted p-value <0.05. Given the three timepoints from the IGRA+ individuals 200 
and the two timepoints from the healthy control groups, we employed both quadratic and linear 201 
approaches to account for all the potential curve shapes in the gene expression data.  202 
 203 
Estimations of relative cellular abundances were calculated from the normalised full gene 204 
expression matrix (58,201 gene probes) using CibersortX [11], which uses gene expression data to 205 
deconvolve mixed cell populations. We used the LM22 [12] leukocyte gene signature matrix as 206 
reference, that comprises 22 different immune cell types, and ran 1,000 permutations. Total 207 
monocyte fraction was calculated as the sum of the fractions of monocytes, macrophages and 208 
dendritic cells. Total lymphocyte fraction was calculated as the sum of B cells, Plasma cells, CD8+ T 209 










polynomial model (degrees of freedom = 2) was fitted in R to estimate relationships between the 211 
monocyte: lymphocyte ratio and time, in IGRA+ subgroups A and B.  212 
 213 
3 RESULTS 214 
 215 
3.1 Recruitment of participants 216 
Thirty adult IGRA-positive (IGRA+) participants were recruited to the study in the period October 217 
2016 to January 2018, of whom 20 took a 12-week course of daily combined rifampicin/ isoniazid 218 
(RH) as preventive therapy (PT) and completed study follow-up. Adult IGRA-negative (IGRA-) 219 
healthy volunteers were recruited to the study and completed a two-week course of daily RH. 220 
After quality control and pre-processing, 18 IGRA+ individuals and 4 IGRA- healthy controls were 221 
taken forward for comparator analyses (Figure 1 and Supplementary figures 1 and 2). Recent 222 
exposure to drug-susceptible pulmonary TB was confirmed for 15/18 IGRA+s. There were no 223 
significant differences in age, gender, ethnicity or BCG status between the 18 IGRA+s and 4 IGRA- 224 
healthy controls (Table 1). 225 
 226 
3.2 Comparing gene expression profiles for IGRA+ versus IGRA- participants 227 
First, we evaluated whether there were discernable differences in gene expression between the 228 
IGRA+ participants and IGRA- healthy controls, using linear models[8]. In the unstimulated 229 
PAXgene blood samples, no transcripts were found to be significantly differentially expressed 230 
(SDE) between the IGRA+ and IGRA- participants at baseline (V1) or visit 2 (V2) (Benjamini-231 
Hochberg [BH] corrected p value < 0.05).  232 
 233 
In this study, QuanitFERON-TB Gold Plus TB1 and TB2 tubes were used to stimulate whole blood. 234 
While both tubes contain peptides from ESAT-6 and CFP-10 Mycobacterium tuberculosis (Mtb) 235 
antigens, the TB1 tube peptides are designed to stimulate CD4+ T cells, and the TB2 peptides to 236 
stimulate both CD4+ and CD8+ T cells [13]. In contrast to the PAXgene tube whole blood samples, 237 
in the TB1-stimulated samples, 123 transcripts were SDE between IGRA+ and IGRA- individuals in 238 
the baseline (V1) samples and 93 were SDE between IGRA+ and IGRA- individuals in the V2 239 
samples (BH corrected p value < 0.05) (Figure 2A and 2B and listed in Supplementary File 1). In the 240 
TB2-stimulated blood samples, when IGRA+ individuals were compared to IGRA-, 43 transcripts 241 










(Figure 2C and 2D and listed in Supplementary File 1). In summary, in vitro stimulation was 243 
necessary to distinguish the IGRA+ group from the IGRA- group. 244 
 245 
3.3 Effects of stimulation on whole blood gene expression 246 
In addition to the TB1 and TB2 Mtb-peptide-containing tubes, the QuantiFERON-TB Gold Plus kit 247 
also includes a “negative” tube which contains no mycobacterial antigen peptides We assessed 248 
the effects of stimulation by comparing gene expression in the TB1- and TB2- stimulated tubes 249 
versus the negative tube at visit 1, using paired t-tests. In the IGRA+ group, when TB1 tube 250 
samples were compared to the negative tube, 3578 transcripts were SDE, while 3217 transcripts 251 
were SDE in the TB2 tube samples versus the negative tube samples (BH corrected p value < 0.05), 252 
2495 of which overlapped with the TB1 comparison (Supplementary figure 3A and 3B; SDE 253 
transcripts listed in Supplementary File 2). No genes were found to be SDE for the TB1- versus  254 
TB2-stimulated samples comparison.  255 
 256 
In the IGRA- healthy controls, 37 transcripts were SDE in the TB1-stimulated samples compared to 257 
the negative tubes at visit 1 whereas just four transcripts were SDE in the TB2-stimulated samples 258 
(BH corrected p value < 0.05) (Supplementary figure 3C and 3D; SDE transcripts listed in 259 
Supplementary File 3). 260 
 261 
3.4 Filtering the gene expression dataset  262 
Analyses were focused on the stimulated samples, as there had been no detectable differences 263 
between the IGRA+ and IGRA- participants in the unstimulated PAXgene samples. As described 264 
above, stimulation induced changes in gene expression in the IGRA- healthy controls, with a higher 265 
number of SDE genes observed with TB1-stimulation than TB2- stimulation, suggesting a greater 266 
non-specific effect independent of Mtb infection in the TB1 stimulation. We were concerned these 267 
non-specific effects could provide interference, so focused on the TB2-stimulated samples for the 268 
next stage of the analysis.  269 
 270 
The gene set was filtered to eliminate noise. Expression values of the 58,201 transcripts ranged 271 
from 4.4 to 18.7, so a conservative noise threshold of 6 was chosen. Of the remaining 34,110 272 










for the analysis as described in 2.5. Through this process, a dataset with the “most variable genes” 274 
was generated for the TB2-stimulated samples (474 transcripts, listed in Supplementary File 4).  275 
 276 
3.5 Clustering analysis of longitudinal gene expression 277 
We hypothesised that the IGRA+ group is heterogeneous, containing individuals with viable 278 
mycobacteria who would demonstrate a transcriptomic response to PT, and IGRA+ individuals 279 
without viable mycobacteria, who would not demonstrate a transcriptomic response to PT and 280 
would more closely resemble the healthy control IGRA- group. To unmask the PT-specific 281 
transcriptomic responses, we sought to stratify the IGRA+ group of individuals in an agnostic way.  282 
We employed unsupervised clustering analysis of longitudinal gene expression in the 18 IGRA+ 283 
patients and the 4 IGRA- controls, aiming to identify IGRA+ subgroups, using the most variable 474 284 
transcripts in the TB2-stimulated dataset. The BClustLong package in ‘R’ [14] was utilised, which 285 
uses a linear mixed-effects framework to model the trajectory of genes over time and bases 286 
clustering on the regression coefficients obtained from all genes.  287 
 288 
This longitudinal clustering analysis revealed two subgroups of IGRA+ participants. One subgroup 289 
of IGRA+s (IGRA+ subgroup A, N=12) clustered with the four healthy controls (Cluster 1), 290 
suggesting their gene expression over time was more similar to this Mtb-unexposed IGRA- 291 
population than it was to the remaining IGRA+s (IGRA+ subgroup B, N=6) who formed Cluster 2. 292 
There were no significant differences in age, gender, ethnicity, BCG vaccination status or the 293 
IGRA+ participants’ TB contact history between clusters 1 and 2 (Table 2).  294 
 295 
3.6 Longitudinal differential gene expression analysis  296 
In order to unravel the underlying blood transcriptomic differences between the two cluster 297 
groups generated by the unsupervised clustering, we performed longitudinal differential gene 298 
expression analysis using MaSigPro package in R [10].   MaSigPro identifies genes with significant 299 
temporal expression changes and genes which are significantly differentially expressed between 300 
groups.  301 
 302 
Of the 474 transcripts in the dataset, 117 transcripts corresponding to 109 genes, were SDE over 303 
time between the two patient groups (with degrees of freedom=1 capturing linear trends, BH 304 










linear terms associated with time (P2RY6, SLC2A3).  Setting the degrees of freedom to 2, 69 out of 306 
the 117 genes were SDE over time between the two cluster groups  (BH corrected p value < 0.05, 307 
listed in Supplementary File 5), while 4 of these genes (MSR1, MT1CP, IGHG3, IGHG1) also had 308 
significant linear and quadratic terms associated with time. In comparing Cluster 1  versus Cluster 309 
2, when one of the clusters is heterogeneous (IGRA+ subgroup A plus IGRA- healthy controls), it is 310 
expected that some of the differences will be due to the IGRA+ subgroup B versus IGRA- 311 
comparison and not the IGRA+ subgroup B vs IGRA+ subgroup A comparison. 312 
 313 
3.7 Biological relevance of the significantly differentially expressed genes 314 
The biological relevance of the 117 transcripts significantly differentially expressed over time 315 
between the two patient cluster groups was investigated. Around one quarter of these SDE genes 316 
have been previously reported in transcriptomics studies comparing blood from TB patients with 317 
healthy controls (31 transcripts, 25 genes) or with other diseases (9 transcripts, 7 genes) [15-21]; 318 
(Supplementary File 5). Functional classification of these genes using PANTHER [22, 23] revealed 319 
that 44/84 of the coding genes encode proteins with specific immunological functions, including 320 
cytokines, cytokine receptors and cytokine signaling (12), chemokines and chemokine-like proteins 321 
(11), immunoglobulins (9), immune cell receptors (4), antimicrobial peptides (3), complement (1) 322 
and antigen presentation (1) (Supplementary File 6). 323 
 324 
Coefficients obtained using MaSigPro were used to cluster significant genes with similar 325 
longitudinal expression patterns (Figure 3). Often the proteins contained within a gene set had 326 
similar function, such as the CXC chemokines CXCL9, 10 and 11 in gene set 2 which were more 327 
highly expressed in patient cluster 2 and increased at V2, and the pro-inflammatory NF-κB 328 
transcription factor-inducing proteins IFNγ, IL-1R associated kinase 2 (IRAK2) and TNF superfamily 329 
member 15 (TNFSF15) in gene set 4, which were more highly expressed in patient cluster 2 and 330 
decreased through PT. BATF2, GCH1 and GBP3 all grouped in gene set 9, with consistently higher 331 
expression in patient cluster 2. Gene expression was higher in patient cluster 1 in only one gene 332 
set (gene set 3). 333 
 334 
Biological pathways analysis was performed using Reactome pathway knowledgebase [24], with 335 
80/117 transcripts successfully mapping to the database. Eleven pathways  had significant over-336 
representation of transcripts within our dataset (BH corrected p value < 0.05; listed in 337 









related to chemokine receptor binding, cytokine signaling – including IL10, TNF and regulatory T 339 
cells, metal ion binding and Complement cascade activation. There were a further 39 pathways 340 
with borderline over-representation: these largely encompassed biological functions related to 341 
innate immunity, antimicrobial peptides, phagocytosis, intracellular infection, and further cytokine 342 
signaling and Complement activation pathways.  343 
 344 
3.8 Differing cellular responses to preventive therapy 345 
Relative cellular abundances were estimated from the gene expression data using CibersortX [11]. 346 
The estimated abundances of monocytes and lymphocytes were used to calculate the monocyte: 347 
lymphocyte ratio (MLR) for the two cluster groups at all three visits. At visits 1 and 3, the MLRs 348 
were similar between Clusters 1 and 2. However, at Visit 2, they were higher in Cluster 2 (median= 349 
0.52) compared to Cluster 1 (median= 0.29, p=0.03). This difference at Visit 2 remained when the 350 
IGRA- healthy controls were removed from the analysis, with the MLR higher in IGRA+ subgroup B 351 
(median=0.52) compared to subgroup A (median=0.35, p=0.04) (Figure 4A).  352 
 353 
Using a second-degree polynomial model, the MLR was found to change over the time-course of 354 
the study period in IGRA+ subgroup B, and was close to the threshold of significance (linear term 355 
p=0.07, quadratic term p=0.06). This was not observed in IGRA+ subgroup A (linear term p=0.6, 356 
quadratic term p=0.8) (Figure 4B and C).   357 
 358 
The relative abundances of other cell types including total monocytes, total lymphocytes, total 359 
CD4+ T cells and neutrophils were also observed to change with time in IGRA+ subgroup B and not 360 
subgroup A (Supplementary figure 4).   361 
 362 
4 DISCUSSION 363 
 364 
This analysis has demonstrated that IGRA+ participants could be stratified according to their whole 365 
blood transcriptome into two distinct populations, one of which clustered with IGRA-, tuberculosis 366 
(TB)-unexposed controls. This separation was not clearly discernible when the transcriptomes of 367 
participants were evaluated at baseline in unstimulated whole blood, but rather was unmasked by 368 











We hypothesised that PT would mediate mycobacterial death in participants for whom IGRA 371 
positivity was attributable to ongoing viable Mycobacterium tuberculosis (Mtb) infection and that 372 
the resulting immunological response, detected as a whole blood transcriptomic readout, would 373 
differentiate such individuals from a group of IGRA+  participants in whom PT would have no anti-374 
mycobacterial effect due to the absence of viable Mtb. Our agnostic clustering approach clustered 375 
all four IGRA- healthy controls with a subgroup of IGRA+s (IGRA+ A), which is strongly suggestive 376 
that if indeed these clusters do define Mtb viability status then the true latent tuberculosis 377 
infection (LTBI) participants lie within the other subgroup (IGRA+ B). The genes differentially 378 
expressed between the two clusters through PT were predominantly involved in the immune 379 
system, particularly related to intracellular infection, inflammation, chemotaxis and cytokine 380 
signalling, indicating a biologically plausible specific response in the IGRA+ B subgroup.   381 
 382 
Alternative explanations for the clear separation of these two groups were considered. Rifampicin 383 
has important antimicrobial effects against gram-positive organisms and can eliminate upper 384 
respiratory tract carriage of gram-negative organisms such as Neisseria meningitidis and 385 
Haemophilus influenzae within 2-4 days. The inclusion of rifampicin/isoniazid treated, IGRA-386 
negative control participants was an attempt to capture and isolate any such non-387 
mycobactericidal effect. In the absence of microbiological sampling and/or microbiome analysis 388 
we cannot entirely exclude the possibility that the separation of the groups is attributable to an 389 
effect completely unrelated to Mtb infection; however two factors which weigh against this 390 
alternative explanation are the low prevalence of N. meningitidis and H. influenzae carriage in this 391 
population (<10% combined) and the identification amongst the differentially expressed genes of 392 
several genes known to be associated with Mtb response pathways. The changes through PT 393 
overlapped with reported changes in blood transcriptome during treatment of active TB cases [25, 394 
26] and during Isoniazid PT [27]. The monocyte-to-lymphocyte ratio transiently increased only in 395 
the IGRA+ B subgroup: this ratio has been linked with TB disease susceptibility and blood 396 
transcriptomes [28]. The prevalence of carriage of non-tuberculous mycobacteria in this London-397 
resident population would also be expected to be very low. We considered the possibility that our 398 
observations could reflect differences in drug metabolism. Rifampicin induces gene expression 399 
changes in hepatocytes [29, 30], but after reviewing this literature and publicly available RNASeq 400 
data (Gene Expression Omnibus, Series GEO139896) [29] we found no evidence for this (data not 401 
shown). This could also be attributed to the fact that our study focused on peripheral blood 402 










these previously reported studies To further investigate any non-specific effects of Rifampicin and 404 
Isoniazid, we also compared gene expression at Visit 2 versus Visit 1 in the healthy controls, using 405 
a paired t- test in limma, and found no significantly differentially expressed genes.  Finally, we 406 
were concerned to exclude all possible artefactual explanations related to sample handling and 407 
found no effect association with study site, time to sample processing, study personnel or date of 408 
enrolment. 409 
 410 
We contend that interferon gamma release assays (IGRA) and tuberculin skin tests (TST) are mis-411 
represented as tests for LTBI, a term which infers viability of Mtb with potential to cause future 412 
reactivation disease. We believe that the observation that 90% of individuals with positive testing 413 
by IGRA/TST do not develop TB disease is more likely to reflect low frequency of persistent viable 414 
(“reactivate-able”) infection than low frequency of breakout of Mtb replication from long-term 415 
immunological control. The empirical evidence that we present in support of this contention is 416 
consistent with recent re-evaluations of epidemiological data which suggest that (1) duration of 417 
Mtb infection viability is likely to be much shorter than previously believed  [31] and that (2) 418 
reactivation rates in IGRA or TST positive individuals unprotected by PT undergoing 419 
immunosuppressive therapy are much lower than would be expected if such testing represented 420 
infection truly capable of reactivation [32]. Emerging mathematical modelling outputs add weight 421 
to this paradigm shift, suggesting that a significant proportion of Mtb-infected individuals achieve 422 
self-clearance, leaving a much smaller population with persisting viable Mtb infection than 423 
previously assumed [33]. Finally, a precedent for lasting anti-mycobacterial immunological 424 
reactivity in the absence of bacterial viability already exists in the form of erythema nodosum 425 
leprosum, type II reactions to persistent M. leprae antigens which are known to occur years after 426 
mycobacterial cure. 427 
 428 
These blood transcriptional responses to PT suggest that around one third of our IGRA+ study 429 
participants had true (viable) LTBI. This study was performed in TB contacts with recent exposure, 430 
who are an IGRA+ population at high risk of progression.  The proportion with viable infection is 431 
predicted to be lower with increasing remoteness in time since exposure, for example in migrants 432 
now resident in low-incidence countries [31]. The implications for national and global estimates of 433 
LTBI prevalence that rely upon IGRA/ TST data are clear and suggest a large overestimation of the 434 
size of the global reservoir of potentially reactivatable latent infection; we contend that such data 435 










be used more judiciously. Since all incident reactivation arises from the true LTBI pool, the 437 
incidence rate in this subgroup of all IGRA positives will be considerably higher than, for example, 438 
the 0.6 per 100 person-years seen in the placebo arm of a recent vaccine trial [34]. The 439 
development of tools and strategies to readily identify this true LTBI subgroup would facilitate 440 
more efficient targeting of interventions to interrupt reactivation and would accelerate evaluation 441 
of novel interventions because the sample size required for future vaccine trials and trials of 442 
preventive therapy would be considerably reduced. Evaluations of risk factors associated with 443 
infection, premised on the use of IGRA/TST to define infection, have likely been using a very 444 
imperfect endpoint with the associated high likelihood of misclassification error. 445 
 446 
The temporal dynamics of the transcriptomic changes are such that evidence of a response can be 447 
detected as early as 2 weeks into PT. This raises the possibility of a ‘treat and test’ approach to PT 448 
wherein the absence of a specific change in a biomarker (or biomarker profile) at an early time 449 
point, say 2 weeks into treatment, could be interpreted as an indication that further treatment will 450 
have no effect and can then be discontinued. Recent TB host gene expression studies have shown 451 
that biomarker signatures can be shrunk to small sets with the potential to be implemented as 452 
diagnostic or prognostic tests in the field [35-37]. 453 
 454 
This is the first study to look at longitudinal transcriptomic responses in the blood of IGRA+ 455 
individuals post-stimulation during the course of PT. Despite its novelty and strengths, it has a 456 
relatively modest number of participants.  Sequential transcriptomic and cell count differential 457 
testing on a larger study population in which defined secondary cases are identified, with a variety 458 
of exposure histories and diverse PT regimens (including those under investigation for multidrug-459 
resistant LTBI) will help to elucidate the array of responses encountered. The hunt for predictors 460 
of future disease amongst TB- exposed individuals has previously been directed towards 461 
identification of biomarkers indicating increased risk, an approach that risks dismissal of future 462 
changes in the host environment which it might not be possible to anticipate (e.g. transplant 463 
immunosuppression). By removing from the pool of Mtb-sensitised participants (IGRA+ or TST+) a 464 
significant proportion for whom reactivation is biologically impossible (because no viable Mtb 465 
infection remains), the scale of the prevention challenge is drastically reduced and a more efficient 466 











Important implications of a test that can distinguish IGRA+ or TST+ Mtb sensitised individuals at 469 
zero risk of progression/reactivation include drastic reevaluation of the global burden of LTBI, 470 
stratification of preventive therapy and post-exposure vaccine efficacy, higher resolution targeting 471 
of LTBI preventive therapy, potential use as a biomarker for efficacy evaluation of novel PT 472 
regimens for drug-susceptible and drug-resistant-TB, and PT test of cure. 473 
 474 
5 CONCLUSION 475 
 476 
Individuals with immunological memory of a prior encounter with Mtb (commonly referred to as 477 
LTBI) who are treated with PT demonstrate two different phenotypes of transcriptomic response. 478 
We propose that the clear responders are those who had truly viable latent Mtb infection, and 479 
that the minimal responders, in common with the IGRA-negative, previously unexposed healthy 480 
controls, had no viable Mtb organisms and were therefore not truly latently TB infected. 481 
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Table 1 625 
Subject Characteristics. 626 
 IGRA+ group IGRA- Healthy 
control group 
Number 18 4 
Age in years: Median (IQR) 34 (28-38) 28 (27-29) 
Gender 
  
Male  10 (56%) 3 (75%) 





Yes  15 (83%) 0 (0%) 
No  3 (17%) 4 (100%) 
BCG Yes  14 (78%) 2 (50%) 
No  2 (11%) 2 (50%) 
Unknown  2 (11%) 0 (0%) 
Continent of 
Birth 
Africa  4 (22%) 0 (0%) 
Asia 4 (22%) 0 (0%) 
Australasia 0 (0%) 1 (25%) 
Europe  9 (50%) 2 (50%) 
North America  0 (0%) 1 (25%) 
South America  1 (6%) 0 (0%) 
Unknown  0 (0%) 0 (0%) 
Ethnicity Asian
1 
5 (28%) 2 (50%) 
Black
2 
4 (22%) 0 (0%) 
White
3 
8 (44%) 2 (50%) 
Other
4 
1 (6%) 0 (0%) 
1
Includes Bengali, Hong Kong, Kurdish, Sri Lankan, Turkish; 
2
Includes Black African; 
3
Includes White British, 627 
Polish, Romanian, White other; 
4
Includes Latin American, Unknown 628 









Table 2 630 
Characteristics of Cluster groups 1 and 2. 631 
 BClustLong clustering group  
 Cluster 1 Cluster 2 p value 




























Age in years: Median (IQR) 32.5 (24-41) 33.5 (29-38) 0.6 
Gender 
  
Male  9 (56%) 4 (66%) 
1 







Yes  10 (83%) 5 (83%) 
1 
No  2 (17%) 1 (17%) 
BCG Yes  10 (62%) 6 (100%) 
0.2 No  4(25%) 0 (0%) 
Unknown  2 (13%) 0 (0%) 
Continent 
of Birth 
Africa 3 (19%) 1 (17%) 
0.2 
Asia  1 (6%) 3 (50%) 
Australasia 1 (6%) 0 (0%) 
Europe  9 (56%) 2 (33%) 
North America  1(6%) 0 (0%) 
South America  1 (6%) 0 (0%) 
Ethnicity Asian
2 




3 (19%) 1 (17%) 
White
4 
8 (50%) 2 (33%) 
Other
5 




IGRA+ participants only 632 
2
Includes Bengali, Hong Kong, Kurdish, Sri Lankan, Turkish; 
3
Includes Black African; 
4
Includes White British, 633 
Polish, Romanian, White other; 
5
Includes Latin American, Unknown 634 












Figure 1. Study overview, showing patient numbers and exclusions. 638 
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Figure 2. Volcano plots showing genes significantly differentially expressed between IGRA+                                    641 
and IGRA- individuals. Plots are shown for TB1-stimulated samples at Visit (V) 1 [A] and V2 [B] and 642 
TB2-stimulated samples at V1 [C] and V2 [D]. Genes overexpressed in IGRA+s with log2Foldchange 643 
(LFC) >1 and Benjamini-Hochberg adjusted p value <0.05 are shown in red. Genes underexpressed 644 
in IGRA+ individuals with LFC <-1 and BH adjusted p value <0.05 are shown in blue. Genes with LFC 645 
>2.7 and < -1.7 are annotated with their gene symbols. Dotted line denotes the significance cut-off 646 
(BH adjusted p value <0.05). 647 
 648 










Figure 3. Longitudinal differential gene expression analysis between patient cluster groups 1 and 650 
2 in TB2-stimulated whole blood samples. With 1 degree of freedom, 117/474 transcripts were 651 
SDE over time and between cluster groups 1 and 2 (BH corrected p value < 0.05). The coefficients 652 
obtained were used to group together significant genes with similar longitudinal expression 653 
patterns. MaSigPro identified 9 gene groups. Plots of gene expression against time for these gene 654 
groups are shown for patient cluster groups 1 (green) and 2 (blue). Lines join the median 655 
expression values of the gene groups at each timepoint. The gene symbols are listed for each gene 656 
group. 657 
 658 










Figure 4: Longitudinal changes in monocyte: lymphocyte ratio through preventive therapy in 660 
IGRA+ subgroups A and B. Cibersortx was used to estimate the abundance of monocytes and 661 
lymphocytes in the TB2-stimulated whole blood samples at each visit, and the monocyte: 662 
lymphocyte ratio was calculated. (A) Boxplots showing the Monocyte: Lymphocyte ratios at Visits 663 
1, 2 and 3 for IGRA- healthy controls and IGRA+ groups A and B. NS denotes p >0.05, * denotes 664 
p≤0.05.  Scatterplots showing the change in Monocyte: lymphocyte ratio over the time-course of 665 
the study period for (B) IGRA+ subgroup A and (C) IGRA+ subgroup B, where Visit 1 is 0 weeks, Visit 666 











SUPPLEMENTARY DATA 669 
 670 
Supplementary Files 671 
 672 
Supplementary File 1: Significantly differentially expressed (SDE) transcripts IGRA+ vs IGRA- in TB1 673 
tubes at Visit (V) 1 and V2 and in TB2 tubes at V1 and V2. 674 
Supplementary File 2: SDE transcripts TB1 vs negative tube, TB2 vs negative tube at V1, in IGRA+. 675 
Supplementary File 3: SDE transcripts TB1 vs negative tube, TB2 vs negative tube at V1, in IGRA-. 676 
Supplementary File 4: 474 most variable transcripts (TB2-stimulated samples). 677 
Supplementary File 5: MaSigPro results: transcripts SDE though time, Cluster 1 vs Cluster 2. 678 
Supplementary File 6: Functional classification of transcripts differentially expressed between 679 
Cluster 1 and Cluster 2. 680 
Supplementary File 7: Results of biological pathways analysis using Reactome pathway 681 
knowledgebase. 682 
 683 










Supplementary Figures 685 
 686 
Supplementary Figure 1. Principle component analyses of the initial gene expression sets. Plots 687 
showing dimensions 1 and 2 of the principle component analyses of the PAXgene samples (A) and 688 
the stimulated samples (B) before ComBat correction. In the stimulated samples, a healthy control 689 
(HC52) was an outlier in dimensions 1 and 2 (circled) and this persisted after batch correction (not 690 
shown), so HC52 was excluded from the subsequent analyses. 691 
 692 










Supplementary Figure 2. Principle component analyses of the gene expression sets before and 694 
after ComBat.  Gene expression data from 18 IGRA+ and 4 IGRA- participants were included in the 695 
final analyses. Batch correction was performed with ComBat. Plots showing dimensions 1 and 2 of 696 
the principle component analyses of the PAXgene tube samples before (A) and after ComBat (B); 697 
all stimulated samples (TB1, TB2 and Negative) before (C, D) and after ComBat (E, F) with C and E 698 
showing batch differentiation and D and F showing tube differentiation; TB1 samples before (G) 699 
and after Combat (H); TB2 samples before (I) and after Combat (J). Batch, visit, IGRA status and 700 
QuantiFERON TB Gold plus tube are provided.  701 
 702 
 703 










Supplementary Figure 3. Volcano plots showing genes significantly differentially expressed 705 
between stimulated (QuantiFERON Gold Plus TB1 and TB2 tubes) and unstimulated 706 
(QuantiFERON Gold Plus negative tubes) blood samples. Plots are shown for IGRA+ subjects, 707 
comparing TB1 vs. negative tube samples (A), and TB2 vs. negative tube samples (B) at visit 1. Also 708 
shown are plots for IGRA- subjects, comparing TB1 vs. negative tube samples (C), and TB2 vs. 709 
negative tube samples (D) at visit 1. Genes overexpressed in stimulated blood with 710 
log2Foldchange (LFC) >1 and BH adjusted p value <0.05 are shown in red. Genes underexpressed 711 
in stimulated blood with LFC <-1 and BH adjusted p value <0.05 are shown in blue. Genes with LFC 712 
>2.7 and < -1.7 are annotated with their gene symbols. Dotted line denotes the significance cut-off 713 
(BH adjusted p value <0.05).  714 
 715 











Supplementary Figure 4. Longitudinal changes in cellular populations through preventive 718 
therapy in IGRA+ subgroups A and B. Cibersortx was used to estimate the abundance of different 719 
cell types in the TB2-stimulated whole blood samples at each visit. Scatterplots showing the 720 
change cellular fractions over the time-course of the study period in IGRA+ subgroups A and B for 721 
Total monocyte fraction (A), Total lymphocyte fraction (B), Total CD4+ T cell fraction (C), 722 
Neutrophil fraction (D). Visit 1 is 0 weeks, Visit 2 is 2 weeks and Visit 3 is 13 weeks, with 90% 723 
confidence intervals shown.  724 
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